Corneal Ulcer: Clinical Trials

9 trials for Corneal Ulcer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 recruiting, 2 unknown. 9 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 5, Recruiting 2, Unknown 2
Phase 22Unknown 2

Follow Corneal Ulcer: new trials by email Literature Review of Corneal Ulcer trials Research Report on Corneal Ulcer

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
Cyclosporine A, Placebo Comparator: Placebo - Fungal Keratitis, Corneal Ulcer
Phase 3RecruitingUniversity of California, San Francisco1502025-09-012026-06-05
Parasitic Ulcer Treatment Trial
Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo - Acanthamoeba Keratitis
Phase 3RecruitingJeremy Keenan, MD, MPH2322024-07-012026-10-01
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears - Keratitis, Corneal Ulcer
Phase 2 / Phase 3UnknownPeschke GmbH4882022-03-142022-10-28
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears - Keratitis, Corneal Ulcer
Phase 2 / Phase 3UnknownPeschke GmbH4682022-03-142022-10-28
Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
Intrastromal voriconazole, Natamycin - Corneal Ulcer, Fungal Keratitis
Phase 3CompletedUniversity of California, San Francisco702016-09-012025-09-25
Cross-linking for Corneal Ulcers Treatment Trial
Corneal Cross-linking, Anti Fungal Drug - Corneal Ulcer, Infectious Keratitis
Phase 3CompletedUniversity of California, San Francisco1472015-11-012025-06-18
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
T4020, Vehicle - Keratitis, Corneal Ulcer
Phase 3CompletedLaboratoires Thea1522013-02-012019-10-23
The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
Voriconazole, Placebo - Corneal Ulcer, Eye Infections, Fungal
Phase 3CompletedUniversity of California, San Francisco2402010-05-012019-02-26
Mycotic Ulcer Treatment Trial I
Natamycin, Voriconazole - Corneal Ulcer, Eye Infections, Fungal
Phase 3CompletedUniversity of California, San Francisco3232010-04-012018-08-01

Narrower conditions

Keratitis (4)  ·  Corneal Diseases (2)  ·  Eye Diseases (2)  ·  Eye Infections, Fungal (2)  ·  Mycoses (2)  ·  Ulcer (2)  ·  Acanthamoeba Keratitis (1)

Broader conditions

Eye Infections (9)  ·  Infections (9)  ·  Corneal Diseases (7)  ·  Eye Diseases (7)  ·  Keratitis (5)  ·  Bacterial Infections and Mycoses (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Amebiasis (1)  ·  Eye Infections, Parasitic (1)  ·  Parasitic Diseases (1)  ·  Protozoan Infections (1)

Interventions

Lubricant Eye Drops (2)  ·  Natamycin (2)  ·  Riboflavin (2)  ·  Voriconazole (2)  ·  Adrenal Cortex Hormones (1)  ·  Corneal Cross-Linking (1)  ·  Cyclosporine (1)  ·  Pharmaceutical Vehicles (1)  ·  polihexanide (1)

Sponsors

University of California, San Francisco (5)  ·  Peschke GmbH (2)  ·  Jeremy Keenan, MD, MPH (1)  ·  Laboratoires Thea (1)

Countries

United States (8)  ·  India (6)  ·  Brazil (1)  ·  France (1)  ·  Nepal (1)  ·  United Kingdom (1)

Top investigators

Bala Ambati (2)  ·  NV Prajna, DNB, FRC Ophth (2)  ·  Nisha Acharya, MD, MS (2)  ·  Tom Lietman, MD (2)  ·  Yvette Viscuso (2)  ·  Gerami D Seitzman, MD (1)  ·  Gerami Seitzman, MD (1)  ·  Jennifer R Rose-Nussbaumer, MD (1)  ·  Jennifer Rose-Nussbaumer, MD (1)  ·  Jeremy Keenan, MD, MPH (1)

Results publications

PMID 35024776, PMID 23702779, PMID 25764482, PMID 26531051, PMID 27054515, PMID 27787540, PMID 28426856, PMID 28817744, PMID 31619359, PMID 32557558, PMID 33031809, PMID 33079921, PMID 35044972, PMID 40372030

NIH funding

U10EY018573 (2), UG1EY033284 (1)